Le Lézard
Classified in: Health
Subjects: NPT, PER

Premera Blue Cross Names Dr. Romilla Batra as Chief Medical Officer, Senior Vice President


MOUNTLAKE TERRACE, Wash., May 2, 2024 /PRNewswire/ -- Premera Blue Cross, a leading health plan in the Pacific Northwest, today announced Dr. Romilla Batra joined the company as Senior Vice President and Chief Medical Officer.

"Romilla brings a profound understanding of clinical strategy and an enduring commitment to improve the member experience, making her an excellent choice as our new Chief Medical Officer," said Lee McGrath, Executive Vice President of Healthcare Services, Premera Blue Cross. "Her strong leadership and passion for advancing the healthcare industry will be pivotal in achieving our vision of delivering access to affordable, quality care for our members. We're excited for this new chapter of leadership at Premera."

Dr. Batra has accountability for the company's clinical strategy, focused on making healthcare work better for Premera members and improving the provider experience. She has oversight of teams focused on population health, quality, healthcare performance, clinical programs, utilization management and medical policy.

"I'm inspired by Premera's deep commitment to our members," Dr. Batra said. "In my new role, I look forward to strengthening our provider partnerships in delivering high-quality care to our members. Additionally, I'm excited to refine our clinical strategy by elevating health equity, population health programs and quality measures to improve the overall health outcomes and experiences of our members."

Prior to joining Premera, Dr. Batra spent more than 12 years at SCAN Health Plan, a national not-for-profit Medicare Advantage plan based in California. She served as their Chief Medical Officer for nearly nine years where she was accountable for SCAN's overall clinical strategy and operations.

Previously, Dr. Batra ran primary care clinics at University of California Irvine and Indiana University. She is an internist by training and continues to volunteer and teach in the medical and business schools at University of California Irvine. She holds a Doctor of Medicine degree from UCLA and a Master of Business Administration from the Paul Merage School of Business at the University of California Irvine.

About Premera Blue Cross
Premera Blue Cross, a not-for-profit, independent licensee of the Blue Cross Blue Shield Association based in Mountlake Terrace, Wash., is a health plan in the Pacific Northwest, providing comprehensive health benefits and tailored services to more than 2.7 million people, from individuals to Fortune 100 companies. For more information, visit www.premera.com.

SOURCE Premera Blue Cross


These press releases may also interest you

at 07:00
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality ?a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company ? continues the fight to increase equity in clinical trials with the next phase of...

at 06:52
According to the latest BCC Research study, the demand for the Global Prenatal Testing Market is expected to grow from $10.9 billion in 2023 and is projected to reach $19.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 12.6%...

at 06:32
"According to the latest BCC Research study, the demand for Medical Robotics and Computer-assisted Surgery: The Global Market is expected to grow from $11.5 billion in 2023 and is projected to reach $19.5 billion by the end of 2028, at a compound...

at 06:15
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...



News published on and distributed by: